AKBLF
Price:
$40.65
Market Cap:
$55.40B
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe, North America, and other international regions. These offerings include immunotherapy products delivered through injections, sublingual drops, and oral tablets, designed to address various allergies such as those caused by house dust mites, grass, tree, ragweed, and Japanese cedar. ALK-Abelló also manufactures adrenaline auto-injectors for the critical management of severe allergic reactions and produces diagnostic tools essential for identifying allergic co...[Read more]
Industry
Biotechnology
IPO Date
2009-11-16
Stock Exchange
OTC
Ticker
AKBLF
According to ALK-Abelló A/S’s latest financial reports and current stock price. The company's current PE Ratio is 45.17. This represents a change of 20.91% compared to the average of 37.36 of the last 4 quarters.
The mean historical PE Ratio of ALK-Abelló A/S over the last ten years is 106.92. The current 45.17 PE Ratio has changed 4.12% with respect to the historical average. Over the past ten years (40 quarters), AKBLF's PE Ratio was at its highest in in the March 2017 quarter at 1.23K. The PE Ratio was at its lowest in in the June 2017 quarter at -2381.37.
Average
106.92
Median
42.78
Minimum
-355.43
Maximum
1.14K
Discovering the peaks and valleys of ALK-Abelló A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 450.08%
Maximum Annual PE Ratio = 1.14K
Minimum Annual Increase = -419.71%
Minimum Annual PE Ratio = -355.43
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 42.33 | -2.08% |
| 2024 | 43.23 | -6.01% |
| 2023 | 46.00 | -27.20% |
| 2022 | 63.19 | -63.15% |
| 2021 | 171.50 | -84.91% |
| 2020 | 1.14K | -419.71% |
| 2019 | -355.43 | 450.08% |
| 2018 | -64.62 | 38.40% |
| 2017 | -46.69 | -240.06% |
| 2016 | 33.33 | 34.70% |
The current PE Ratio of ALK-Abelló A/S (AKBLF) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
43.86
5-year avg
73.25
10-year avg
106.92
ALK-Abelló A/S’s PE Ratio is greater than Laboratorios Farmaceuticos Rovi, S.A. (22.57), greater than Zealand Pharma A/S (3.10), greater than Shanghai Junshi Biosciences Co., Ltd. (-46.29), greater than InnoCare Pharma Limited (23.37), greater than Genscript Biotech Corporation (-5.97), greater than Camurus AB (publ) (45.17), greater than Clicks Group Limited (17.19), greater than Fielmann AG (17.88), greater than Getinge AB (publ) (22.39), greater than COSMOS Pharmaceutical Corporation (15.14),
| Company | PE Ratio | Market cap |
|---|---|---|
| 22.57 | $4.63B | |
| 3.10 | $3.16B | |
| -46.29 | $4.84B | |
| 23.37 | $2.32B | |
| -5.97 | $3.50B | |
| 45.17 | $3.21B | |
| 17.19 | $3.34B | |
| 17.88 | $4.17B | |
| 22.39 | $5.10B | |
| 15.14 | $2.94B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALK-Abelló A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ALK-Abelló A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ALK-Abelló A/S's PE Ratio?
How is the PE Ratio calculated for ALK-Abelló A/S (AKBLF)?
What is the highest PE Ratio for ALK-Abelló A/S (AKBLF)?
What is the 3-year average PE Ratio for ALK-Abelló A/S (AKBLF)?
What is the 5-year average PE Ratio for ALK-Abelló A/S (AKBLF)?
How does the current PE Ratio for ALK-Abelló A/S (AKBLF) compare to its historical average?